Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [31] Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?
    Avedissian, Sean N.
    Pais, Gwendolyn M.
    Liu, Jiajun
    Rhodes, Nathaniel J.
    Scheetz, Marc H.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (02) : 426 - 432
  • [32] Comparison of acute kidney injury in patients prescribed vancomycin in combination with piperacillin-tazobactam or cefepime for diabetic foot infections
    Piccuirro, Sarah R.
    Casapao, Anthony M.
    Claudio, Alyssa M.
    Isache, Carmen
    Jankowski, Christopher A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (04) : 893 - 896
  • [33] Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam
    Shao, Chi-Hao
    Tai, Chih-Hsun
    Lin, Fang-Ju
    Wu, Chien-Chih
    Wang, Jann-Tay
    Wang, Chi-Chuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (01) : 117 - 125
  • [34] Incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Carrington, Julia
    Beardsley, James
    Williamson, John
    Johnson, James
    Bowline, Isai
    PHARMACOTHERAPY, 2016, 36 (12): : E242 - E242
  • [35] We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?
    Cotta, Menino Osbert
    Roberts, Jason A.
    Lipman, Jeffrey
    CRITICAL CARE, 2016, 20
  • [36] Outcomes of Extended-Infusion Piperacillin-Tazobactam: A Retrospective Analysis of Critically Ill Patients
    Lee, Grace C.
    Liou, Hansheng
    Yee, Russell
    Quan, Clifford F.
    Neldner, Katherine
    CLINICAL THERAPEUTICS, 2012, 34 (12) : 2297 - 2300
  • [37] Risk of kidney injury in patients on concomitant oral vancomycin and piperacillin-tazobactam: Analysis of the pharmacovigilance database in Japan
    Mitsuboshi, Satoru
    Katagiri, Hiroki
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 (01) : 208 - 212
  • [38] Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin-Tazobactam: A Retrospective Cohort Analysis
    Rutter, W. Cliff
    Burgess, Donna R.
    Talbert, Jeffery C.
    Burgess, David S.
    JOURNAL OF HOSPITAL MEDICINE, 2017, 12 (02) : 77 - 82
  • [39] Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study
    Yamashita, Yuma
    Kawaguchi, Hiroshi
    Yano, Tsubasa
    Sakurai, Norihiro
    Shibata, Wataru
    Oshima, Kazuhiro
    Imai, Takumi
    Yamada, Koichi
    Nakamura, Yasutaka
    Nagayama, Katsuya
    Kakeya, Hiroshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (11) : 1614 - 1620
  • [40] Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem
    Al Yami, Majed S.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2017, 10 (06) : 770 - 773